Compare RMCO & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCO | IMMP |
|---|---|---|
| Founded | 2021 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.2M | 31.5M |
| IPO Year | 2021 | 2012 |
| Metric | RMCO | IMMP |
|---|---|---|
| Price | $2.03 | $3.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 9.2K | ★ 30.6K |
| Earning Date | 11-13-2026 | 09-01-2026 |
| Dividend Yield | ★ 0.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,949,916.00 | N/A |
| Revenue This Year | $61.62 | N/A |
| Revenue Next Year | $62.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 513.30 | N/A |
| 52 Week Low | $1.74 | $0.26 |
| 52 Week High | $5.00 | $5.36 |
| Indicator | RMCO | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 49.75 |
| Support Level | $1.90 | $3.06 |
| Resistance Level | $2.46 | $3.55 |
| Average True Range (ATR) | 0.14 | 0.34 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 38.00 | 41.09 |
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.